Item 1. Condensed Consolidated Financial
Statements
Q BIOMED INC.
Condensed Consolidated Balance Sheets
|
|
May 31, 2019
|
|
|
November 30, 2018
|
|
|
|
(Unaudited)
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash
|
|
$
|
178,715
|
|
|
$
|
2,684,413
|
|
Prepaid expenses
|
|
|
28,546
|
|
|
|
12,500
|
|
Total current assets
|
|
|
207,261
|
|
|
|
2,696,913
|
|
Intangible assets, net
|
|
|
475,000
|
|
|
|
500,000
|
|
Total Assets
|
|
$
|
682,261
|
|
|
$
|
3,196,913
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable and accrued expenses
|
|
$
|
1,113,091
|
|
|
$
|
392,230
|
|
Accrued expenses - related party
|
|
|
7,500
|
|
|
|
7,500
|
|
Accrued interest payable
|
|
|
171,784
|
|
|
|
29,639
|
|
Investor advances
|
|
|
80,750
|
|
|
|
-
|
|
Total current liabilities
|
|
|
1,373,125
|
|
|
|
429,369
|
|
|
|
|
|
|
|
|
|
|
Long-term liabilities:
|
|
|
|
|
|
|
|
|
Convertible notes payable, net
|
|
|
3,669,612
|
|
|
|
2,873,272
|
|
Total long term liabilities
|
|
|
3,669,612
|
|
|
|
2,873,272
|
|
Total Liabilities
|
|
|
5,042,737
|
|
|
|
3,302,641
|
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies (Note 6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders’ Deficit:
|
|
|
|
|
|
|
|
|
Preferred stock, $0.001 par value; 100,000,000 shares authorized; no shares issued and outstanding as of May 31, 2019 and November 30, 2018
|
|
|
-
|
|
|
|
-
|
|
Common stock, $0.001 par value; 250,000,000 shares authorized; 14,677,136 and 14,290,236 shares issued and outstanding as of May 31, 2019 and November 30, 2018, respectively
|
|
|
14,676
|
|
|
|
14,290
|
|
Additional paid-in capital
|
|
|
33,002,224
|
|
|
|
31,994,129
|
|
Accumulated deficit
|
|
|
(37,377,376
|
)
|
|
|
(32,114,147
|
)
|
Total Stockholders’ Deficit
|
|
|
(4,360,476
|
)
|
|
|
(105,728
|
)
|
Total Liabilities and Stockholders’ Deficit
|
|
$
|
682,261
|
|
|
$
|
3,196,913
|
|
The accompanying notes are an integral
part of these condensed consolidated financial statements
Q BioMed Inc.
Condensed Consolidated Statements of
Operations
(Unaudited)
|
|
For the three months ended May 31,
|
|
|
For the six months ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General and administrative expenses
|
|
$
|
1,195,759
|
|
|
$
|
1,230,616
|
|
|
$
|
2,438,470
|
|
|
$
|
2,551,370
|
|
Research and development expenses
|
|
|
1,071,416
|
|
|
|
782,188
|
|
|
|
1,886,115
|
|
|
|
1,635,613
|
|
Total operating expenses
|
|
|
2,267,175
|
|
|
|
2,012,804
|
|
|
|
4,324,585
|
|
|
|
4,186,983
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
369,972
|
|
|
|
-
|
|
|
|
660,644
|
|
|
|
-
|
|
Change in fair value of embedded derivatives
|
|
|
251,000
|
|
|
|
-
|
|
|
|
278,000
|
|
|
|
-
|
|
Total other expenses
|
|
|
620,972
|
|
|
|
-
|
|
|
|
938,644
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(2,888,147
|
)
|
|
$
|
(2,012,804
|
)
|
|
$
|
(5,263,229
|
)
|
|
$
|
(4,186,983
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share - basic and diluted
|
|
$
|
(0.20
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
(0.36
|
)
|
|
$
|
(0.31
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding, basic and diluted
|
|
|
14,577,312
|
|
|
|
13,982,627
|
|
|
|
14,491,881
|
|
|
|
13,358,654
|
|
The accompanying notes are an integral part
of these condensed consolidated financial statements
Q BIOMED INC.
Condensed Consolidated Statements of
Changes in Shareholders’ Equity (Deficit)
(Unaudited)
|
|
For the Three months Ended May 31, 2019
|
|
|
|
Common Stock
|
|
|
Additional Paid
|
|
|
Accumulated
|
|
|
Total
Stockholders’
|
|
|
|
Shares
|
|
|
Amount
|
|
|
in Capital
|
|
|
Deficit
|
|
|
Deficit
|
|
Balance as of February 28, 2019
|
|
|
14,466,155
|
|
|
$
|
14,465
|
|
|
$
|
32,477,729
|
|
|
$
|
(34,489,229
|
)
|
|
$
|
(1,997,035
|
)
|
Share based compensation for services
|
|
|
210,981
|
|
|
|
211
|
|
|
|
524,495
|
|
|
|
-
|
|
|
|
524,706
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(2,888,147
|
)
|
|
|
(2,888,147
|
)
|
Balance as of May 31, 2019
|
|
|
14,677,136
|
|
|
$
|
14,676
|
|
|
$
|
33,002,224
|
|
|
$
|
(37,377,376
|
)
|
|
$
|
(4,360,476
|
)
|
|
|
For the Three Months Ended May 31, 2018
|
|
|
|
Common Stock
|
|
|
Additional Paid
|
|
|
Accumulated
|
|
|
Total
Stockholders’
|
|
|
|
Shares
|
|
|
Amount
|
|
|
in Capital
|
|
|
Deficit
|
|
|
Equity
|
|
Balance as of February 28, 2018
|
|
|
13,947,784
|
|
|
$
|
13,948
|
|
|
$
|
28,622,798
|
|
|
$
|
(25,017,549
|
)
|
|
$
|
3,619,197
|
|
Share based compensation for services
|
|
|
39,346
|
|
|
|
39
|
|
|
|
279,947
|
|
|
|
-
|
|
|
|
279,986
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(2,012,804
|
)
|
|
|
(2,012,804
|
)
|
Balance as of May 31, 2018
|
|
|
13,987,130
|
|
|
$
|
13,987
|
|
|
$
|
28,902,745
|
|
|
$
|
(27,030,353
|
)
|
|
$
|
1,886,379
|
|
|
|
For the Six Months Ended May 31, 2019
|
|
|
|
Common Stock
|
|
|
Additional Paid
|
|
|
Accumulated
|
|
|
Total
Stockholders’
|
|
|
|
Shares
|
|
|
Amount
|
|
|
in Capital
|
|
|
Deficit
|
|
|
Deficit
|
|
Balance as of November 30, 2018
|
|
|
14,290,236
|
|
|
$
|
14,290
|
|
|
$
|
31,994,129
|
|
|
$
|
(32,114,147
|
)
|
|
$
|
(105,728
|
)
|
Share based compensation for services
|
|
|
386,900
|
|
|
|
386
|
|
|
|
1,008,095
|
|
|
|
-
|
|
|
|
1,008,481
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(5,263,229
|
)
|
|
|
(5,263,229
|
)
|
Balance as of May 31, 2019
|
|
|
14,677,136
|
|
|
$
|
14,676
|
|
|
$
|
33,002,224
|
|
|
$
|
(37,377,376
|
)
|
|
$
|
(4,360,476
|
)
|
|
|
For the
Six Months Ended May 31, 2018
|
|
|
|
Common Stock
|
|
|
Additional Paid
|
|
|
Accumulated
|
|
|
Total
Stockholders’
|
|
|
|
Shares
|
|
|
Amount
|
|
|
in Capital
|
|
|
Deficit
|
|
|
Equity
|
|
Balance as of November 30, 2017
|
|
|
12,206,409
|
|
|
$
|
12,206
|
|
|
$
|
23,187,408
|
|
|
$
|
(22,843,370
|
)
|
|
$
|
356,244
|
|
Share based compensation for services
|
|
|
68,846
|
|
|
|
69
|
|
|
|
771,798
|
|
|
|
-
|
|
|
|
771,867
|
|
Issuance of common stock and warrants for cash, net of offering costs
|
|
|
1,711,875
|
|
|
|
1,712
|
|
|
|
4,943,539
|
|
|
|
-
|
|
|
|
4,945,251
|
|
Net loss
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
(4,186,983
|
)
|
|
|
(4,186,983
|
)
|
Balance as of May 31, 2018
|
|
|
13,987,130
|
|
|
$
|
13,987
|
|
|
$
|
28,902,745
|
|
|
$
|
(27,030,353
|
)
|
|
$
|
1,886,379
|
|
The accompanying notes are an integral
part of these condensed consolidated financial statements
Q BIOMED INC.
Condensed Consolidated Statements of
Cash Flows
(Unaudited)
|
|
For the six months ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(5,263,229
|
)
|
|
$
|
(4,186,983
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities
|
|
|
|
|
|
|
|
|
Share based compensation for services
|
|
|
1,008,481
|
|
|
|
771,867
|
|
Change in fair value of embedded conversion option
|
|
|
278,000
|
|
|
|
-
|
|
Accretion of debt discount
|
|
|
518,340
|
|
|
|
-
|
|
Amortization expense
|
|
|
25,000
|
|
|
|
-
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
Prepaid expenses
|
|
|
(16,046
|
)
|
|
|
-
|
|
Accounts payable and accrued expenses
|
|
|
720,861
|
|
|
|
(30,747
|
)
|
Accrued interest payable
|
|
|
142,145
|
|
|
|
-
|
|
Net cash used
in operating activities
|
|
|
(2,586,448
|
)
|
|
|
(3,445,863
|
)
|
|
|
|
|
|
|
|
|
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Proceeds from investor advances
|
|
|
80,750
|
|
|
|
-
|
|
Proceeds received for issuance of common stock and warrants, net of offering costs
|
|
|
-
|
|
|
|
4,945,251
|
|
Net cash provided
by financing activities
|
|
|
80,750
|
|
|
|
4,945,251
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash
|
|
|
(2,505,698
|
)
|
|
|
1,499,388
|
|
|
|
|
|
|
|
|
|
|
Cash at beginning of period
|
|
|
2,684,413
|
|
|
|
824,783
|
|
Cash at end of period
|
|
$
|
178,715
|
|
|
$
|
2,324,171
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures:
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
-
|
|
|
$
|
-
|
|
Cash paid for income taxes
|
|
$
|
-
|
|
|
$
|
-
|
|
The accompanying notes are an integral part
of these condensed consolidated financial statements
Q BIOMED INC.
Notes to Condensed Consolidated Financial
Statements
Note 1 - Organization of the Company
and Description of the Business
Q BioMed Inc. (“Q BioMed” or
“the Company”), incorporated in the State of Nevada on November 22, 2013, is a biomedical acceleration and development
company focused on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. Q BioMed intends
to mitigate risk by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and
sectors. The Company intends to develop these assets to provide returns via organic growth, revenue production, out-licensing,
sale or spinoff new public companies.
On December 7, 2016, the Company formed
its wholly-owned subsidiary in Cayman Islands, “Q BioMed Cayman SEZC” (the “Subsidiary”). The accompanying
condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiary. All intercompany
balances and transactions have been eliminated in consolidation.
Note 2 - Basis of Presentation
The accompanying interim period unaudited
condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the
United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission
(“SEC”) regarding interim financial reporting. These condensed consolidated financial statements are unaudited and should
be read in conjunction with the audited consolidated financial statements included in the Company’s Annual Report on Form
10-K for the year ended November 30, 2018. Certain disclosures included in the annual financial statements have been condensed
or omitted from these financial statements as they are not required for interim financial statements under U.S. GAAP and the rules
of the SEC. These unaudited consolidated financial statements reflect all adjustments that are, in the opinion of management, necessary
for a fair statement of the results for the interim periods presented. These adjustments are of a normal, recurring nature. Interim
period operating results may not be indicative of the operating results for a full year.
The Company currently operates in one business
segment focusing on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. The Company
is not organized by market and is managed and operated as one business. A single management team reports to the chief operating
decision maker, the Chief Executive Officer, who comprehensively manages the entire business. The Company does not currently operate
any separate lines of business.
Going Concern
The accompanying condensed consolidated
financial statements are prepared assuming the Company will continue as a going concern, which contemplates the realization of
assets and liquidation of liabilities in the normal course of business.
The Company has and is expected to incur
net losses and cash outflows from operations in pursuit of extracting value from its acquired intellectual property. These matters,
amongst others, raise doubt about the Company’s ability to continue as a going concern.
The Company has not generated any revenue
from operations since inception and has limited assets upon which to commence its business operations. Management anticipates
that the Company will have to raise additional funds and/or generate revenue from drug sales within twelve months to continue operations.
Additional funding will be needed to implement the Company’s business plan that includes various expenses such as fulfilling
our obligations under licensing agreements, legal, operational set-up, general and administrative, marketing, employee salaries
and other related start-up expenses. Obtaining additional funding will be subject to a number of factors, including general market
conditions, investor acceptance of our business plan and initial results from our business operations. These factors may impact
the timing, amount, terms or conditions of additional financing available to us. If the Company is unable to raise sufficient funds,
management we will be forced to scale back the Company’s operations or cease our operations.
Management has determined that there is
substantial doubt about the Company’s ability to continue as a going concern within one year after the condensed consolidated financial
statements are issued. The accompanying condensed consolidated financial statements do not include any adjustments relating
to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result
from this uncertainty.
Note 3 - Summary of Significant Accounting
Policies
The Company’s significant accounting
policies are disclosed in the audited financial statements for the year ended November 30, 2018 included in the Company’s
Form 10-K. Since the date of such financial statements, there have been no changes to the Company’s significant accounting
policies.
Q BIOMED INC.
Notes to Condensed Consolidated Financial Statements
Recent accounting pronouncements
On February 2016, the FASB issued ASU No. 2016-02,
Leases (Topic
842)
. Under the new guidance, lessees will be required to recognize all leases (with the exception of short-term leases) on
the balance sheet as a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured
on a discounted basis and a right-of-use asset, which is an asset that represents the lessee¹s right to use, or control the
use of, a specified asset for the lease term. The guidance in ASU 2017-11 is effective for the Company on December 1, 2019.
Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is
currently evaluating the impact of the new standard on its condensed consolidated financial statements.
In July 2017, the FASB issued ASU 2017-11,
Earnings
Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting
for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable
Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception.
The ASU allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion
feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features)
with down round features may no longer be required to be accounted classified as liabilities. A company will recognize the value
of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding
financial instruments, such as warrants, an entity will treat the value of the effect of the down round, when triggered, as a dividend
and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with
embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial
conversion discount to be amortized to earnings. The guidance in ASU 2017-11 is effective for the Company on December 1, 2019.
Early adoption is permitted, and the guidance is to be applied using a full or modified retrospective approach. The Company is
currently evaluating the impact of the new standard on its condensed consolidated financial statements.
Recent adopted pronouncements
In May 2014, the FASB issued ASU 2014-09,
Revenue from Contracts with Customers (Topic 606), as modified by ASU 2015-14, Revenue from Contracts with Customers (Topic
606): Deferral of the Effective Date
, ASU 2016-08,
Revenue from Contracts with Customers (Topic 606): Principal versus
Agent Considerations (Reporting Revenue Gross versus Net),
ASU 2016-10,
Revenue from Contracts with Customers (Topic 606):
Identifying Performance Obligations and Licensing
, and ASU 2016-12,
Revenue from Contracts with Customers (Topic 606):
Narrow-Scope Improvements and Practical Expedients
. The revenue recognition principle in ASU 2014-09 is that an entity should
recognize revenue to depict the transfer of goods or services to customers in an amount that reflects the consideration to which
the entity expects to be entitled in exchange for those goods or services. In addition, new and enhanced disclosures will be required.
Companies may adopt the new standard either using the full retrospective approach, a modified retrospective approach with practical
expedients, or a cumulative effect upon adoption approach. The adoption of this standard on December 1, 2018 did not impact
the Company’s condensed consolidated financial statements.
In August 2016, the FASB issued ASU No.
2016-15,
Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments
. This new standard
clarifies certain aspects of the statement of cash flows, including the classification of debt prepayment or debt extinguishment
costs or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of
the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims,
proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investees and
beneficial interests in securitization transactions. This new standard also clarifies that an entity should determine each separately
identifiable source of use within the cash receipts and payments on the basis of the nature of the underlying cash flows. In situations
in which cash receipts and payments have aspects of more than one class of cash flows and cannot be separated by source or use,
the appropriate classification should depend on the activity that is likely to be the predominant source or use of cash flows for
the item. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed consolidated financial
statements.
In June 2018, the FASB issued ASU 2018-07,
Compensation - Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting
. This ASU is intended
to simplify aspects of share-based compensation issued to non-employees by making the guidance consistent with the accounting for
employee share-based compensation. The adoption of this standard on December 1, 2018 did not impact the Company’s condensed
consolidated financial statements.
Note 4 - Loss per share
Basic net loss per share was calculated
by dividing net loss by the weighted-average common shares outstanding during the period. Diluted net loss per share
was calculated by dividing net loss by the weighted-average common shares outstanding during the period using the treasury stock
method or the two-class method, whichever is more dilutive. The table below summarizes potentially dilutive securities that
were not considered in the computation of diluted net loss per share because they would be anti-dilutive.
|
|
May 31,
|
|
Potentially dilutive securities
|
|
2019
|
|
|
2018
|
|
Warrants
|
|
|
4,984,000
|
|
|
|
4,878,000
|
|
Convertible Notes
|
|
|
2,092,000
|
|
|
|
-
|
|
Stock Options
|
|
|
1,200,000
|
|
|
|
500,000
|
|
Q BIOMED INC.
Notes to Condensed Consolidated Financial Statements
Note 5 - Convertible Notes
|
|
May 31, 2019
|
|
|
November 30,
2018
|
|
Convertible Notes:
|
|
|
|
|
|
|
|
|
Principal value
|
|
$
|
4,000,000
|
|
|
$
|
4,000,000
|
|
Fair value of bifurcated contingent put option
|
|
|
540,000
|
|
|
|
262,000
|
|
Debt discount
|
|
|
(870,388
|
)
|
|
|
(1,388,728
|
)
|
Carrying value of convertible notes
|
|
|
3,669,612
|
|
|
|
2,873,272
|
|
Total long-term carrying value of convertible notes
|
|
$
|
3,669,612
|
|
|
$
|
2,873,272
|
|
The monthly payment provision within
the convertible notes is a contingent put option that is required to be separately measured at fair value, with subsequent changes
in fair value recognized in the Condensed Consolidated Statement of Operations. The fair value estimate is a Level 3 measurement.
The Company estimated the fair value of the monthly payment provision by estimating the probability of the occurrence of a
Triggering Date and applying the probability to the discounted maximum redemption premium for any given payment with the following
key inputs:
|
|
May 31, 2019
|
|
November 30, 2018
|
Stock price
|
|
$1.53
|
|
$1.95 - $2.97
|
Terms (years)
|
|
0.8
|
|
1.2 - 1.4
|
Volatility
|
|
84.61%
|
|
72.1% - 76.5%
|
Risk-free rate
|
|
2.21% - 2.38%
|
|
2.4% - 2.5%
|
Dividend yield
|
|
0.00%
|
|
0.00%
|
Discount rate
|
|
35.17%
|
|
35.17%
|
Amortization of the debt discount associated
with the convertible notes was approximately $282,000 and $518,000 for the three-month and six-month periods ended May 31, 2019,
respectively, and was included in interest expense in the accompanying Condensed Consolidated Statements of Operations.
Note 6 - Commitments and Contingencies
Legal
Periodically, the Company reviews the status
of significant matters, if any exist, and assesses our potential financial exposure. If the potential loss from any claim or legal
claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal
proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals
are based on the best information available at the time. As additional information becomes available, the Company reassesses
the potential liability related to pending claims and litigation.
On December 28, 2018, the Company commenced
litigation against BioNucleonics, Inc. (“BNI”) and parties related to BNI in the Supreme Court of New York, New York
County (removed to federal court in February 2019). The litigation stems from a license agreement that the Company entered into
with BNI in 2016 and amended from time to time. Under the agreement with BNI, the Company were granted a worldwide, exclusive license
on certain BNI intellectual property and the option to acquire the BNI IP within three years of the agreement. The BNI IP consists
of generic Strontium Chloride SR89 (generic Metastron®) (“SR89”) and all of BNI’s intellectual property relating
to it (“BNI IP”). SR89 is a radiopharmaceutical therapeutic for cancer bone pain therapy.
The Company believes that it has fulfilled
the obligations under the agreement to exercise an option to acquire the BNI IP and has notified BNI of such exercise, but BNI
has not transferred the BNI IP to the Company. As a result, the Company has commenced litigation to, among other actions, obtain
all of the BNI IP. The Company also seeks judgments against BNI and related parties for the misappropriation of funds, breach of
contract, fraud and fraudulent inducement. In February 2019, such lawsuit was removed to the Federal court located in the Southern
District of New York.
Q BIOMED INC.
Notes to Condensed Consolidated Financial Statements
Advisory Agreements
The Company entered into customary consulting
arrangements with various counterparties to provide consulting services, business development and investor relations services,
pursuant to which the Company agreed to issue shares of common stock as services are received.
Lease Agreement
In December 2016, the Subsidiary entered
into a lease agreement for its office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement
ends in December 2019 and can be renewed for another three years.
Rent expense is classified within general
and administrative expenses on a straight-line basis and included in the accompanying Condensed Consolidated Statements of Operations
as follows:
|
|
For the three months ended May 31,
|
|
|
For the six months ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Rent expense
|
|
$
|
7,500
|
|
|
$
|
7,500
|
|
|
$
|
15,000
|
|
|
$
|
15,000
|
|
License Agreement
Mannin
On October 29, 2015, the Company entered
into a Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby the
Company was granted a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”)
which initially focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive
License.
On March 26, 2019, the Company entered
into an amendment to the Patent and Technology License and Purchase Option Agreement that it initially entered into with Mannin
Research Inc. on October 29, 2015 (the “Mannin Agreement”). Under such amendment, the term of the option granted under
the Mannin Agreement was extended to October 29, 2021 in exchange for the Company issuing 100,000 shares to Mannin Research Inc.
on April 9, 2019.
During the six months ended May 31, 2019
and 2018, the Company incurred approximately $1,277,000 and $1,220,000, respectively, in research and development expenses to fund
the costs of development of the eye drop treatment for glaucoma pursuant to the Exclusive License.
Washington University
On March 9, 2019, the Company entered into
an Exclusive License Agreement with Washington University for license of a diagnostic marker for determining the severity of glaucoma
using the expression levels of Growth Differentiation Factor 15. The agreement calls for the Company to pay an initial fee of approximately
$88,000, pay annual maintenance fees ranging from $15,000 to $75,000, make additional payments upon the following milestones:
|
·
|
The first commercial sale of a companion diagnostic
product;
|
|
·
|
Initiation of a clinical trial for a diagnostic product
to support FDA PMA or 510(k) regulatory approval or the foreign equivalent;
|
|
·
|
PMA or 510(k) regulatory approval by the FDA or the
foreign equivalent; and
|
|
·
|
The first commercial sale of a diagnostic product.
|
In additional to the above payments, royalty
payments based upon sales of a companion diagnostic product or diagnostic product are required.
Q BIOMED INC.
Notes to Condensed Consolidated Financial Statements
Note 7 - Related Party Transactions
The Company entered into consulting agreements
with certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from
such agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements
of Operations as follows:
|
|
For the three months ended May 31,
|
|
|
For the six months ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Consulting and legal expenses
|
|
$
|
90,000
|
|
|
$
|
60,000
|
|
|
$
|
192,446
|
|
|
$
|
120,000
|
|
Note 8 - Stockholders’ Equity
Deficit
As of May 31, 2019 and November 30, 2018,
the Company is authorized to issue up to 250,000,000 shares of its $0.001 par value common stock and up to 100,000,000 shares of
its $0.001 par value preferred stock.
Issuance of shares for services
During the six months ended May 31, 2019,
the Company issued an aggregate of 386,900 shares of the Company common stock to various vendors for advisory services, valued
at approximately $728,000 based on the estimated fair market value of the stock on the date of grant and was recognized within
general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations.
Note 9 - Warrants and Options
Summary of warrants
The following represents a summary of all
outstanding warrants to purchase the Company’s common stock, including warrants issued to vendors for services and warrants
issued as part of the units sold in the private placements, at May 31, 2019 and the changes during the period then ended:
|
|
Warrants
|
|
|
Weighted
Average
Exercise Price
|
|
|
Weighted
Average
Remaining Contractual
Life (years)
|
|
|
Intrinsic Value
|
|
Outstanding at November 30, 2018
|
|
|
4,984,058
|
|
|
$
|
3.48
|
|
|
|
3.51
|
|
|
$
|
250,000
|
|
Issued
|
|
|
-
|
|
|
$
|
-
|
|
|
|
-
|
|
|
$
|
-
|
|
Expired
|
|
|
-
|
|
|
$
|
-
|
|
|
|
-
|
|
|
$
|
-
|
|
Outstanding at May 31, 2019
|
|
|
4,984,058
|
|
|
$
|
3.48
|
|
|
|
3.01
|
|
|
$
|
40,000
|
|
Exercisable at May 31, 2019
|
|
|
4,902,058
|
|
|
$
|
3.50
|
|
|
|
2.99
|
|
|
$
|
40,000
|
|
Fair value of all outstanding warrants
issued to non-employees for services was calculated with the following key inputs:
|
|
For the six months ended May 31,
|
|
|
2018
|
Stock price
|
|
$2.92 - $3.40
|
Term (years)
|
|
2.0 - 4.3
|
Volatility
|
|
124.88% - 130.31%
|
Risk-free rate
|
|
2.25% - 2.68%
|
Dividend yield
|
|
0.00%
|
There were no warrants issued for the six months ended May 31,
2019.
Q BIOMED INC.
Notes to Condensed Consolidated Financial Statements
Options issued for services
The following represents a summary of all
outstanding options to purchase the Company’s common stock at May 31, 2019 and the changes during the period then ended:
|
|
Options
|
|
|
Weighted
Average
Exercise Price
|
|
|
Weightd
Average
Remaining
Contractual
Life (years)
|
|
|
Intrinsic Value
|
|
Outstanding at November 30, 2018
|
|
|
900,000
|
|
|
$
|
3.68
|
|
|
|
3.99
|
|
|
$
|
-
|
|
Issued
|
|
|
300,000
|
|
|
$
|
1.53
|
|
|
|
5.00
|
|
|
$
|
-
|
|
Outstanding at May 31, 2019
|
|
|
1,200,000
|
|
|
$
|
3.15
|
|
|
|
3.87
|
|
|
$
|
-
|
|
Exercisable at May 31, 2019
|
|
|
975,000
|
|
|
$
|
3.52
|
|
|
|
3.61
|
|
|
$
|
-
|
|
Fair value of options issued in the six-month
period ended May 31, 2018 was calculated with the following key inputs. No options were granted in the six-month period ended May
31, 2019.
|
|
For the six months ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
Exercise price
|
|
$
|
1.53
|
|
|
$
|
3.00
|
|
Expected term (years)
|
|
|
5.0
|
|
|
|
5.0
|
|
Volatility
|
|
|
98.75
|
%
|
|
|
127.70
|
%
|
Risk-free rate
|
|
|
2.03
|
%
|
|
|
2.52
|
%
|
Dividend yield
|
|
|
0.00
|
%
|
|
|
0.00
|
%
|
Stock-based Compensation
Stock-based compensation expense is classified
within general and administrative expenses as a result of the shares, outstanding warrants and options issued to consultants and
employees and included in the accompanying Condensed Consolidated Statements of Operations as follows:
|
|
For the three months ended May 31,
|
|
|
For the six months ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Stock-based compensation expense
|
|
|
123,000
|
|
|
|
164,000
|
|
|
|
280,000
|
|
|
|
567,000
|
|
As of May 31, 2019, the estimated unrecognized
stock-based compensation associate with these agreements is approximately $319,000 and will be fully recognized over the next seven
months.
Item 2. Management’s Discussion and Analysis of Financial
Condition and Results of Operation
Forward-Looking Statements
This Quarterly Report contains forward-looking
statements about our business, financial condition and prospects that reflect management’s assumptions and beliefs based
on information currently available. The expectations indicated by such forward-looking statements might not be realized. If
any of our management’s assumptions should prove incorrect, or if any of the risks and uncertainties underlying such expectations
should materialize, our actual results may differ materially from those indicated by the forward-looking statements.
The key factors that are not within our
control and that may have a direct bearing on operating results include, but are not limited to, acceptance of our services, our
ability to create and expand our customer base, managements’ ability to raise capital in the future, the retention of key
employees and changes in the regulation of our industry.
There may be other risks and circumstances
that management may be unable to predict. When used in this Quarterly Report, words such as,
“believes,” “expects,”
“intends,” “plans,” “anticipates,” “estimates”
and similar expressions are intended
to identify forward-looking statements, although there may be certain forward-looking statements not accompanied by such expressions.
Overview
Q BioMed Inc. (or “the Company”)
was incorporated in the State of Nevada on November 22, 2013 and is a biomedical acceleration and development company focused
on licensing, acquiring and providing strategic resources to life sciences and healthcare companies. We intend to mitigate risk
by acquiring multiple assets over time and across a broad spectrum of healthcare related products, companies and sectors. We
intend to develop these assets to provide returns via organic growth, revenue production, out-licensing, sale or spin out.
Recent Developments
Metastron/Strontium89 Chloride USP Injection
We have been working hard to commercialize
both our Strontium-89 products. In addition to the global exclusive license to generic Strontium-89 from BioNucleonics Inc. (“BNI”),
we accelerated our global commercial launch by purchasing the Metastron
TM
brand from GE Healthcare in November of 2018.
As a result, we now control significant market share for this injectable non-opioid metastatic cancer palliation drug in North
America and much of the world. Metastron is approved for sale in 22 countries as a non-opioid therapy for the debilitating pain
associated with metastatic skeletal cancer. As part of the Metastron acquisition, we agreed to transition manufacturing to another
facility and chose IsoTherapeutics to be that manufacturer in parallel with our Strontium-89 product.
The FDA approval of IsoTherapeutics to
produce a commercial drug product is one of several milestone catalysts we expect to positively impact our business over the next
few months. Our Strontium-89 products are our lead revenue opportunities and an important step for both Q BioMed and the many patients
that will benefit from finally having access to the non-opioid palliation treatments. Once the FDA approves IsoTherapeutics Group
to manufacture product, this radiopharmaceutical is well positioned to generate revenues in 2019 and beyond.
Although the commercial manufacturing approval
process has taken longer than anticipated, we are now more confident than ever in the timing around the commercial launch. Our
contract manufacturer expects to complete the final site modifications required by the FDA after its recent inspection by the end
of the month, after which, a follow up review may be required to approve the application.
In anticipation of the approval, we have
on-boarded our commercial team tasked with infrastructure set-up, including: medical information and pharmacovigilance, government
contracting, marketing, contract sales and telesales. Our distribution partner has been identified with capabilities including
warehousing/inventory management, invoicing and customer service/ordering. It also has a sales team that calls on major providers,
a national network of nuclear pharmacies in the U.S. and distribution and coverage throughout the U.S. We have completed a reimbursement
landscape and set our pricing strategy. Our scientific platform is complete which is informing a creative advertising campaign
to coincide with the commercial launch of our product. We are assembling a world class scientific advisory board specific to this
product to assist in market access and phase 4 clinical trial planning.
Our Strontium-89 radiopharmaceutical drug
products are expected to begin generating revenue this year in the cancer pain palliation market, with a significant opportunity
to expand into a much larger market through our planned phase IV clinical trial designed to expand the label from a pain palliation
to a cancer therapeutic. A similar radiopharmaceutical with a much narrower indication in metastatic disease, but with survival
benefits (two months), was acquired by Bayer for $2.9 billion in 2013 and is expected to have peak sales of a billion dollars.
The acquisition of Metastron has given
Q BioMed access to a global market much sooner than expected and we continue to be extremely excited about its prospects to re-establish
a deserved niche in the late stage cancer treatment landscape.
QBM001
There is currently NO treatment for this
20,000 US and 250,000 worldwide subgroup of autistic children that are minimally verbal or non-verbal. We recently filed for Orphan
Drug Designation with the FDA and look forward to working with the regulators on this application. We worked with 7 centers of
excellence for autism to define a differential diagnosis for our targeted subgroup, and all are on board. We completed a biomarker
study that allows us to better define which children should be included in our planned trial. The biomarker also provided insight
into how to improve the dosing. A very targeted population with an improved, targeted dose, ensures our planned trials is smaller
and greater likelihood of being successful, which we are very excited about. We have completed formulation of a slow release version
of a drug candidate that is required for this clinical application. We know that our target dose is effective and is safer than
a non-formulated drug. We plan on filing an IND and believe the green light will allow us to commence a relatively short pivotal
clinical trial of QBM-001 in early 2020. We expect to see interim data within 6 months of the start of the trial. This would represent
a significant catalyst in 2020 given the acute need for a therapy in this neglected pediatric patient population.
Uttroside-B
Over 40,000 liver cancer patients in
the US are diagnosed every year, and the total diagnoses per year has increased by 3% each year over the last 15 years. Each
patient has a life expectancy of less than four months. Our initial data from both animals and cell lines suggests that our
developing molecule could be very effective - as much as 10 times more effective than current treatments. As a result, we are
very excited to be bringing this product closer to a proof of concept trial. Once demonstrated, we will actively seek
partnerships in order to realize a return on our investment. We are very excited to report that due to the success of our
chemistry teams, we have successfully synthesised Uttroside B. This was a very complicated process and a huge achievement for
them. The synthesized product is now being tested for pre-clinical efficacy in comparison to the natural product.
MAN-01 and GDF15
There are over 60 million patients worldwide
with Primary Open-Angle Glaucoma. MAN-01 aims to reduce the pressure build-up in the eye by assisting with, and correcting, drainage
problems in tiny vessels in the eye called the Schlemm’s Canal. MAN-01 is being designed to target these unique and extremely
important vessels, as over 70% of all fluid in the eye flows through the Schlemm’s Canal. Currently, the MAN-01 program is
finalizing its preclinical lead candidate optimization by completing a series of ophthalmic in vivo studies to demonstrate efficacy.
After successful completion of the in vivo studies, Mannin Research will begin preparing for preclinical toxicology and filing
of its IND. Our research shows that the drug’s mechanism of action may ameliorate vessel damage in several other diseases
such as: kidney disease, cardiovascular disease, and against infectious diseases. We believe these programs comprise a multi-disease
platform technology that has several valuable applications. Adding the GDF15 biomarker to our portfolio is a significant step to
securing a unique product offering that put precision medicine and patient specific treatment in the hands of clinicians. GDF15
is a companion diagnostic marker to the MAN-01 drug for determining the severity of glaucoma using the expression levels of Growth
Differentiation Factor 15 (GDF15). Determining the severity of glaucoma using this biomarker will aid in treatment decisions for
patients diagnosed with, and being treated for, glaucoma. Recent buyouts in the Biotechnology space has us believing that large
pharma companies could be looking for valuable assets like this with multiple downlines because of expiring patient protection
on current drugs. Our collaborators at the Washington University in St. Louis are currently examining the effectiveness of GDF15
as a clinical biomarker in a clinical trial. In parallel, Q BioMed and Mannin Research are working with the Biointerfaces Institute
at McMaster University in Ontario, Canada to develop a GDF15 biomarker diagnostic kit for monitoring glaucoma severity and progression.
The aim is to develop a simple integrated diagnostic test that can be performed at a physician’s office with no external,
expensive equipment.
Financial Overview
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.
Critical Accounting Policies and Estimates
This management’s discussion and
analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which
have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the
reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our condensed
consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to fair
value of financial instruments, research and development costs, accrued expenses and stock-based compensation. We base our estimates
on historical experience, known trends and events and various other factors that we believe to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. Other than
as set out in Note 3 to our accompanying unaudited condensed consolidated financial statements we believe there have been no significant
changes in our critical accounting policies as described in the Form 10-K.
Unaudited Results of Operations for
the three months ended May 31, 2019 and 2018:
|
|
For
the Three Months Ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
General and administrative expenses
|
|
$
|
1,195,759
|
|
|
$
|
1,230,616
|
|
Research and development expenses
|
|
|
1,071,416
|
|
|
|
782,188
|
|
Total operating expenses
|
|
|
2,267,175
|
|
|
|
2,012,804
|
|
|
|
|
|
|
|
|
|
|
Other expenses:
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
369,972
|
|
|
|
-
|
|
Change in fair value of embedded derivatives
|
|
|
251,000
|
|
|
|
-
|
|
Total other expenses
|
|
|
620,972
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(2,888,147
|
)
|
|
$
|
(2,012,804
|
)
|
Operating expenses
We incur various costs and expenses in
the execution of our business. The increase in operating expenses was mainly due to more professional and research & development
fees incurred in connection with the license agreements with Mannin and Washington University.
Other expenses
During the three months ended May 31, 2019,
interest expense increased to $370,000 from $0 in the prior year. Interest expense in the three months ended May 31, 2019 is comprised
of approximately $282,000 accretion of debt discount and approximately $56,000 of accrued interest expense based on the coupon
interest rate of the outstanding debt. During the three months ended May 31, 2019, we recognized a loss of $251,000 resulting from
the change in fair value of embedded contingent put options in convertible notes with a principal balance of $4 million.
Net loss
In the three months ended May 31, 2019
and 2018, we incurred net losses of approximately $2.9 million and $2.0 million, respectively. Our management expects to
continue to incur net losses for the foreseeable future, due to our need to continue to establish a broader pipeline of assets,
expenditure on R&D and implement other aspects of our business plan.
Unaudited Results of Operations for
the six months ended May 31, 2019 and 2018:
|
|
For
the Six Months Ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
Operating expenses:
|
|
|
|
|
|
|
|
|
General and administrative expenses
|
|
$
|
2,438,470
|
|
|
$
|
2,551,370
|
|
Research and development expenses
|
|
|
1,886,115
|
|
|
|
1,635,613
|
|
Total operating expenses
|
|
|
4,324,585
|
|
|
|
4,186,983
|
|
|
|
|
|
|
|
|
|
|
Other expenses:
|
|
|
|
|
|
|
|
|
Interest expense
|
|
|
660,644
|
|
|
|
-
|
|
Change in fair value of embedded derivatives
|
|
|
278,000
|
|
|
|
-
|
|
Total other expenses
|
|
|
938,644
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(5,263,229
|
)
|
|
$
|
(4,186,983
|
)
|
Operating expenses
We incur various costs and expenses in
the execution of our business. The increase in operating expenses was mainly due to more professional and research & development
fees incurred in connection with the license agreements with Mannin and Washington University.
Other expenses
During the six months ended May 31, 2019,
interest expense increased to $661,000 from $0 in the prior year. Interest expense in the six months ended May 31, 2019 is comprised
of approximately $518,000 accretion of debt discount and approximately $111,000 of accrued interest expense based on the coupon
interest rate of the outstanding debt. During the six months ended May 31, 2019, we recognized a loss of $278,000 resulting from
the change in fair value of embedded contingent put options in convertible notes with a principal balance of $4 million.
Net loss
In the six months ended May 31, 2019 and
2018, we incurred net losses of approximately $5.3 million and $4.2 million, respectively. Our management expects to continue
to incur net losses for the foreseeable future, due to our need to continue to establish a broader pipeline of assets, expenditure
on R&D and implement other aspects of our business plan.
Liquidity and Capital Resources
We prepared the accompanying condensed
consolidated financial statements assuming that we will continue as a going concern, which contemplates the realization of assets
and liquidation of liabilities in the normal course of business.
We have not yet established an ongoing
source of revenues and must cover our operating through debt and equity financings to allow us to continue as a going concern.
We had approximately $179,000 in cash as of May 31, 2019. Our ability to continue as a going concern depends on the ability
to obtain adequate capital to fund operating losses until we generate adequate cash flows from operations to fund our operating
costs and obligations. If we are unable to obtain adequate capital, we could be forced to cease operations.
We depend upon our ability, and will continue
to attempt, to secure equity and/or debt financing. We cannot be certain that additional funding will be available on acceptable
terms, or at all. Our management determined that there was substantial doubt about our ability to continue as a going concern within
one year after the condensed consolidated financial statements were issued, and management’s concerns about our ability to
continue as a going concern within the year following this report persist.
The accompanying condensed consolidated
financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts
or amounts and classification of liabilities that might result from this uncertainty.
Cash Flows
The following table sets forth the significant
sources and uses of cash for the periods addressed in this report:
|
|
For
the Six Months Ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
Net cash (used in) provided by:
|
|
|
|
|
|
|
|
|
Operating activities
|
|
$
|
(2,586,448
|
)
|
|
$
|
(3,445,863
|
)
|
Financing activities
|
|
|
80,750
|
|
|
|
4,945,251
|
|
Net (decrease) increase in cash
|
|
$
|
(2,505,698
|
)
|
|
$
|
1,499,388
|
|
Net cash used in operating activities was
approximately $2.6 million for the six months ended May 31, 2019 as compared to approximately $3.4 million for the six months ended
May 31, 2018. The decrease in net cash used in operating activities relates to the net loss of approximately $5.3 million
for the six months ended May 31, 2019, partially offset by aggregate non-cash expenses of approximately $1.8 million and changes
in operating assets and liabilities of approximately $847,000. The net cash used in operating activities of approximately
$3.4 million for the six months ended May 31, 2018 results from the net loss of approximately $4.2 million, partially offset by
aggregate non-cash expenses of approximately $772,000.
Net cash provided by financing activities
was approximately $81,000 for the six months ended May 31, 2019, resulting from proceeds from investor advances. Net cash provided
by financing activities was approximately $4.9 million for the six months ended May 31, 2018, resulting from proceeds received
from the issuance of common stock and warrants of approximately $5.4 million, offset by offering costs of approximately $0.5 million.
Commitments and Contingencies
Legal
On December 28, 2018, we commenced litigation
against BioNucleonics, Inc. (“BNI”) and parties related to BNI in the Supreme Court of New York, New York County. The
litigation stems from a license agreement that we entered into with BNI in 2016 and amended from time to time. Under the agreement
with BNI, we were granted a worldwide, exclusive license on certain BNI intellectual property and the option to acquire the BNI
IP within three years of the agreement. The BNI IP consists of generic Strontium Chloride SR89 (generic Metastron®) (“SR89”)
and all of BNI’s intellectual property relating to it (“BNI IP”). SR89 is a radiopharmaceutical therapeutic for
cancer bone pain therapy.
We believe that we have fulfilled the obligations
under the agreement to exercise an option to acquire the BNI IP and have notified BNI of such exercise, but BNI has not transferred
the BNI IP to us. As a result, we have commenced litigation to, among other actions, obtain all of the BNI IP. We also seek judgments
against BNI and related parties for the misappropriation of funds, breach of contract, fraud and fraudulent inducement. In February
2019, such lawsuit was removed to the Federal court located in the Southern District of New York.
Advisory Agreements
We entered into customary consulting arrangements
with various counterparties to provide consulting services, business development and investor relations services, pursuant to which
we agreed to issue shares of common stock as services are received.
Lease Agreement
In December 2016, we entered into a lease
agreement for office space located in Cayman Islands for $30,000 per annum. The initial term of the agreement ends in December
2019 and can be renewed for another three years.
Rent expense is classified within general
and administrative expenses on a straight-line basis and included in the accompanying Condensed Consolidated Statements of Operations
as follows:
|
|
For the three months ended May 31,
|
|
|
For the six months ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Rent expense
|
|
$
|
7,500
|
|
|
$
|
7,500
|
|
|
$
|
15,000
|
|
|
$
|
15,000
|
|
License Agreement
Mannin
On October 29, 2015, we entered into a
Patent and Technology License and Purchase Option Agreement (“Exclusive License”) with a vendor whereby we were granted
a worldwide, exclusive, license on, and option to, acquire certain intellectual property (“Mannin IP”) which initially
focused on developing a first-in-class eye drop treatment for glaucoma within the four-year term of the Exclusive License.
On March 26, 2019, we entered into an amendment
to the Patent and Technology License and Purchase Option Agreement that it initially entered into with Mannin Research Inc. on
October 29, 2015 (the “Mannin Agreement”). Under such amendment, the term of the option granted under the Mannin Agreement
was extended to October 29, 2021 in exchange for the Company issuing 100,000 shares to Mannin Research Inc. on April 9, 2019.
During the six months ended May 31, 2019
and 2018, we incurred approximately $1,277,000 and $1,220,000, respectively, in research and development expenses to fund the costs
of development of the eye drop treatment for glaucoma pursuant to the Exclusive License.
Washington University
On March 9, 2019, we entered into an Exclusive
License Agreement with Washington University for license of a diagnostic marker for determining the severity of glaucoma using
the expression levels of Growth Differentiation Factor 15. The agreement calls for us to pay an initial fee of approximately $88,000,
pay annual maintenance fees ranging from $15,000 to $75,000, make additional payments upon the following milestones:
|
·
|
The first commercial sale of a companion diagnostic
product;
|
|
·
|
Initiation of a clinical trial for a diagnostic product to support FDA PMA or 510(k) regulatory
approval or the foreign equivalent;
|
|
·
|
PMA or 510(k) regulatory approval by the FDA or the foreign equivalent; and
|
|
·
|
The first commercial sale of a diagnostic product.
|
In additional to the above payments, royalty
payments based upon sales of a companion diagnostic product or diagnostic product are required.
Related Party Transactions
We entered into consulting agreements with
certain management personnel and stockholders for consulting and legal services. Consulting and legal expenses resulting from such
agreements were included within general and administrative expenses in the accompanying Condensed Consolidated Statements of Operations
as follows:
|
|
For the three months ended May 31,
|
|
|
For the six months ended May 31,
|
|
|
|
2019
|
|
|
2018
|
|
|
2019
|
|
|
2018
|
|
Consulting and legal expenses
|
|
$
|
90,000
|
|
|
$
|
60,000
|
|
|
$
|
192,446
|
|
|
$
|
120,000
|
|
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements.